Results 151 to 160 of about 343,983 (293)

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source

Prevalence and risk perceptions of nicotine pouch use: A systematic review of population‐based studies

Addiction, EarlyView.
Abstract Background and Aims Oral nicotine pouches (NPs) are a new class of non‐combustible nicotine products that have gained rapid popularity. Despite rising sales and marketing, evidence of their prevalence and risk perceptions remains limited. This systematic review aimed to synthesize the available global evidence on the prevalence and patterns of
Salma Mahmoodianfard, Spencer Shahen, Javad Heshmati, Emma Bates, Evyanne Quirouette, Terefe Gelibo, Sarah Visintini, Hassan Mir   +7 more
wiley   +1 more source

The Long and Winding Road to Cannabis Legalization [PDF]

In almost all countries supply, distribution and use of cannabis is prohibited. Nevertheless, cannabis is the most popular illicit drug. Prohibition does not seem to work.
Ours, J.C. van
core  

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Alcohol consumption and cognitive function: A systematic review and dose–response meta‐analysis of 20 cohort studies

Addiction, EarlyView.
Abstract Background and aims Amid ongoing debate on whether low‐to‐moderate alcohol consumption reduces cardiovascular risk, studies examining the association between alcohol consumption and cognitive function have reported inconsistent results. To quantitatively assess this association, we conducted a dose–response meta‐analysis of cohort studies ...
Sooyeun Choi, Youjin Je
wiley   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

Addiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Prescribed pharmaceutical alternatives initiative coinciding with reductions in unregulated street opioid use among young people who use drugs: An interrupted time series analysis

Addiction, EarlyView.
Abstract Background and aims In British Columbia, Canada, an initiative was implemented in 2020 to reduce overdose mortality by prescribing pharmaceutical opioids (primarily hydromorphone) as a substitute for the toxic unregulated drug supply. This study estimated changes in the level and trend of unregulated opioid use and non‐prescribed hydromorphone
Erica McAdam, Mohammad Karamouzian, Michael John Milloy, Carmen Verdicchio, Eric C. Sayre, Kanna Hayashi, Thomas Kerr, Kora DeBeck   +7 more
wiley   +1 more source

[Therapeutic indications in lawsuits seeking medical Cannabis in Brazil: a cross-sectional study in light of scientific evidence]. [PDF]

Cad Saude Publica
Pinto CDBS, Ferreira TJN, Oliveira CVDS, Esher Â, Hora MFVMPD, Osorio-de-Castro CGS.   +5 more
europepmc   +1 more source

HSE will reimburse cost of Ava Twomey’s medical cannabis.

, 2018
....Mr Harris previously said the legal issues involved in developing a reimbursement process for cannabis-based products for medicinal use were being examined.
McMahon, Aine
core  

Towards the implementation of cannabis‐focused apps in early intervention services for psychosis: A qualitative investigation of patient and clinician perspectives

Addiction, EarlyView.
Abstract Background and aims Cannabis use is highly prevalent among young adults with first‐episode psychosis (FEP) and is associated with poorer clinical and functional outcomes. Mobile health interventions may help address structural barriers to delivering cannabis‐focused psychosocial interventions within early intervention services (EIS), yet ...
Selim Abou‐Rahal, Alexis Doucet, Pamela Lachance‐Touchette, Amal Abdel‐Baki, Stephanie Coronado‐Montoya, José Côté, Ovidiu Tatar, Philip G. Tibbo, Didier Jutras‐Aswad   +8 more
wiley   +1 more source